Company: INMB
Filing Date: 2025-04-25
Form Type: DEFA14A
Source: 0001213900-25-035538
Chunk: 1

Company: Inmune Bio, Inc.
Filing Date: 2025-04-25
Form: DEFA14A
Chunk 1
---
]hat vote is required in order for the proposals to be approved?” the voting standard for Proposal
5 was improperly stated as “Proposal 5. The Second Amended and Restated 2021 Plan requires the affirmative vote of a majority
of the shares present in person or by proxy.” This Supplement hereby amends and replaces that language with the following:

“Proposal 5.
The Second Amended and Restated 2021 Plan requires the affirmative vote of the majority of shares cast on the proposal.”

On page 12 of the Proxy Statement, the voting standard for Proposal
5 was correctly stated under the caption titled, “Vote Required and Recommendation,” as follows “[t]he approval of the
Second Amended and Restated 2021 Plan will be made upon the affirmative vote of the majority of shares cast on the proposal,” but
improperly stated “[a]bstentions and broker non-votes will have no direct effect on the outcome of this proposal.” This
Supplement hereby amends and replaces that improperly stated language with the following:

“Abstentions and broker-non votes will count towards the quorum
requirement for the annual meeting but will not count as a vote for or against Proposal 5.”

The correction has no effect on the voting standard for Proposal 1,
Proposal 2, Proposal 3 or Proposal 4, each of which was properly stated in the Proxy Statement. This supplement does not change the proposals
to be acted upon at the Annual Meeting, which are described in the Proxy Statement.